

Cellnovo and Roche Sign Commercial Blood Glucose Monitor Agreement

New Cellnovo Handset, Featuring Roche's Leading Blood Glucose Monitoring Platform, Reduces Production Time

Paris, France, March 15, 2016 – Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected all-in-one diabetes management system, today announces the signing of a commercial agreement to integrate Roche Diabetes Care’s market leading Accu-Chek® Aviva and Accu-Chek® Performa blood glucose monitoring (BGM) platforms into the Cellnovo diabetes management system.

Cellnovo will build in the Accu-Chek® Aviva or Accu-Chek® Performa monitoring platforms into its newly developed, next generation e-connected handset which was CE-marked earlier this month. The Roche BGM platform will replace the LifeScan OneTouch® Vita BGM currently used. The redesign of the handset will also enable an increase in productivity at Cellnovo’s manufacturing site, due to a reduced assembly time.

The integrated BGM is an important feature of Cellnovo’s platform. Coupled with the dose calculator developed by Cellnovo, this highly accurate BGM will enable patients to benefit from precise and immediate dose calculations at the time of food intake.

Under the terms of the agreement, Cellnovo will have the rights to sell its integrated system, equipped with Roche’s Accu-Chek® Aviva or Accu-Chek® Performa platforms, across Europe. The new Cellnovo systems will become available over the next month in all current markets, and will be made available in all future markets. The Roche strips used in Cellnovo’s new BGM integrated handsets will be available to patients via existing distribution channels.

Sophie Baratte, Chief Executive Officer of Cellnovo, commented: *“We are delighted to be partnering with Roche Diabetes Care, the world’s number one provider of blood glucose monitoring solutions. This collaboration is a significant endorsement of the Cellnovo technology and commercial approach and supports Cellnovo’s design objective of offering a unique all-in-one system for diabetes management.”*

•••

In the coming months, Cellnovo will participate in the following investor events:

- Portzamparc Small Caps PEA PME Seminar, April 4, Paris
- European 'Smallcap Event', April 11-12, Paris



The First Connected All-in-one Diabetes Management System

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real-time.

For further information please visit www.cellnovo.com

About the Cellnovo Diabetes Management System

Compact, tubeless, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real-time.

About Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 40 years, the Accu-Chek® brand has been dedicated to enable people with diabetes to live life as normal and active as possible as well as to empower healthcare professionals manage their patients' condition in an optimal way. Today, the Accu-Chek® portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management spanning from blood glucose monitoring through information management to insulin delivery. The Accu-Chek® brand encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – leading to an improved medical outcome. For more information, please visit www.accu-chek.com

Contact

Cellnovo

Chief Executive Officer
Sophie Baratte
investors@cellnovo.com

NewCap

Investor Relations
Emmanuel Huynh
+ 33 1 44 71 00 16

Media Relations in France
Nicolas Merigeau
+ 33 1 44 71 94 98
cellnovo@newcap.eu

Consilium Strategic Communications

Media Relations in United Kingdom
Amber Fennell, Chris Gardner, Chris Welsh, Laura Thornton
+44 20 3709 5700
cellnovo@consilium.com

Cellnovo is listed on Euronext,
Compartment C
ISIN: FR0012633360 – Ticker:
CLNV

